Table 1 Assessment of comorbidities in the outcomes of HIV–AIDS inpatients
Clinical data | Death | Discharge | p |
|---|---|---|---|
N = 17 | N = 66 | ||
Age (mean, std.) | 37.6 (9.9) | 36.2 (9.4) | 0.590 |
Gender (male) | 11 (64.7) | 54 (81.8) | 0.184 |
ART | 12 (70.6) | 55 (83.3) | 0.300 |
CD4 T < 350 cells/mL | 14 (82.4) | 58 (87.9) | 0.688 |
HIV-RNA > 1000 copies | 14 (82.4) | 47 (71.2) | 0.539 |
Weight loss | 14 (82.4) | 30 (45.5) | 0.007** |
Very good condition | 7 (41.2) | 35 (53.0) | 0.425 |
Lucid and space-oriented | 8 (47.1) | 40 (60.6) | 0.410 |
Anemia | 15 (88.2) | 43 (65.2) | 0.079 |
Respiratory disorder | 14 (82.4) | 42 (63.6) | 0.244 |
Neurological disorder | 8 (47.1) | 29 (43.9) | 0.999 |
Cardiovascular disorder | 2 (11.8) | 2 (3.0) | 0.184 |
Gastrointestinal disorder | 8 (47.1) | 16 (24.2) | 0.077 |
Active coinfections | |||
 Tuberculosis | 12 (70.6) | 25 (37.9) | 0.026* |
 Parasites in stools | 3 (17.6) | 13 (19.7) | 0.999 |
 Toxoplasmosis IgM | 1 (5.9) | 7 (10.6) | 0.999 |
 Cytomegalovirus IgM | 1 (5.9) | 2 (3.0) | 0.502 |
 Epstein Barr virus IgM | 17 (100) | 66 (100) | 0.999 |
 Herpes virus IgM | 0 (0) | 3 (4.5) | 0.999 |
Previous infections | |||
 HCV IgG | 1 (5.9) | 2 (3.0) | 0.502 |
 Cytomegalovirus IgG | 13 (76.5) | 53 (80.3) | 0.741 |
 Toxoplasmosis IgG | 13 (76.5) | 52 (78.8) | 0.999 |
 Epstein Barr virus IgG | 12 (70.6) | 49 (74.2) | 0.764 |
 Herpes virus IgG | 12 (70.6) | 44 (66.7) | 0.999 |